SBIA
CPRX

Sheaff Brock Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$495K Buy
+20,405
New +$460K 0.05% 255
2023
Q2 		– Sell
-10,527
Closed -$175K – 499
2023
Q1 		$175K Buy
+10,527
New +$174K 0.02% 456

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Sheaff Brock Investment Advisors's CPRX Position: Q1 2025 in Review

Sheaff Brock Investment Advisors opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2025: 20,405 shares worth $495K. The stake represents 0.05% of the portfolio and ranks #255 among its holdings. This is a return to the name: Sheaff Brock Investment Advisors previously reported a position in CPRX as recently as Q1 2023.

Sheaff Brock Investment Advisors first reported a position in CPRX in Q1 2023 and has held it in 2 quarters since. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Sheaff Brock Investment Advisors held 20,405 shares of Catalyst Pharmaceutical worth $495K as of Q1 2025.
  • Catalyst Pharmaceutical was a new Sheaff Brock Investment Advisors position in Q1 2025.
  • Catalyst Pharmaceutical made up 0.05% of Sheaff Brock Investment Advisors's portfolio in Q1 2025, its #255 holding.
  • Sheaff Brock Investment Advisors first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 2 quarters since.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2025, filed 7 May 2025.